Tokyo and Mainz, October 28, 2016 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) and Ganymed Pharmaceuticals AG (CEO; Özlem Türeci, “Ganymed”), a biopharmaceutical company located in Mainz, Germany which focuses on the development of antibodies against cancer, announced today that Astellas and Ganymed’s shareholders have entered into an agreement for Astellas to acquire Ganymed.
All3DP GmbH, operator of a fast growing English-language Internet platform for 3D printing, has completed seven-figure Series A financing round.
On invitation by CatCap Corporate Finance, Merck KGaA, SHS Gesellschaft für Beteiligungsmanagement, Paul Hartmann AG and HTGF , around 60 representatives of the Venture Capital scene met at Merck's innovation center in Darmstadt.
4SC AG (4SC, FSE Prime Standard: VSC) today announced that Dr Daniel Vitt and the Supervisory Board of 4SC have agreed that Daniel Vitt will step down as Chief Development Officer and Chief Scientific Officer (CDO/CSO) as well as from the Management Board of 4SC as of 31 December 2016.
Immunic acquires two promising drug development programs with validated targets known to be relevant in various immune and autoimmune diseases
Continuing to focus the epigenetics strategy on key oncology assets
Together with Merck KGaA, CatCap is hosting a Venture Lounge for Life Sciences in Darmstadt on the 25th of October 2016.
Collaboration will draw upon Genentech’s leading position in cancer immunotherapy and BioNTech’s premier clinical mRNA vaccine platform.
BioNTech AG, a fully integrated biotechnology company developing individualized cancer immunotherapies is pleased to announce that it was presented with the “Emerging Star of the Year Award” at the European Mediscience Awards 2016.
BioNTech Diagnostics GmbH, a fully owned subsidiary of BioNTech AG, and its Chinese partner Shuwen Biotech Co. Ltd. today announced that the Chinese FDA (CFDA) has granted the “Innovative Medical Product” status for MammaTyper®, a real-time PCR kit for breast cancer stratification.
Leon Chen, Thomas Chalberg and Justin Duckworth Join Ethris' Board to Support Next
Stage of Company's Development
AMSilk GmbH, the world's first industrial supplier of synthetic silk molecules, has raised new capital through a further financing round.
Dr. Andreas Rummelt, pharma industry expert and former CEO of Sandoz, was elected as new supervisory board member at LEUKOCARE's annual shareholder meeting on July 12th.
BioNTech AG, a fully integrated biotechnology Company developing individualized cancer immunotherapies is pleased to announce that it was presented with the “Emerging Star of the Year Award” at the European Mediscience Awards 2016.
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) announced today that it entered into a securities purchase agreement for a private placement with a select group of institutional investors, including lead investor BVF Partners L.P. and its affiliates as well as existing and new investors.
Major step towards truly personalized treatment of any cancer
Siemens Healthineers has expanded its diagnostics portfolio with the acquisition of NEO New Oncology AG, Cologne, Germany
MUNICH--(BUSINESS WIRE)--Ethris GmbH, a pioneer in the emerging field of messenger RNA (mRNA) medicine, announced today the publication of a research paper in the peer-reviewed journal “Biomaterials” that underlines the broad therapeutic potential of the company’s proprietary mRNA transcript therapy platform. The paper demonstrates that a modified mRNA construct based on Ethris’ technology coding for the human growth factor BMP-2 (bone morphogenetic protein-2) can induce bone regeneration in three different settings including an established in vivo model for bone healing.
During the 34th JP Morgan Healthcare Conference, the German Accelerator Life Sciences (GALS) announced the first four companies to participate in its Cambridge-based program. AYOXXA Biosystems, PEPperPRINT, Personal MedSystems, and Sonormed will receive support tailored towards the specific needs of each company for up to 12 months. The scope of these young German companies ranges from treating tinnitus patients with filtered music and preventing stroke via a mobile ECG app to novel platform technologies for medical research and diagnostics.